Bausch Health stock rises, Durect flies after acquisition deal

Published 29/07/2025, 14:30
© Reuters.

Investing.com -- Bausch Health Companies Inc. (NYSE:BHC) stock rose 2.2% while Durect Corporation (NASDAQ:DRRX) shares soared 263% after the companies announced a definitive agreement for Bausch Health to acquire Durect.

The acquisition includes Durect’s novel therapeutic molecule, larsucosterol, which has shown promising results in Phase 2 trials for treating alcoholic hepatitis (AH). Under the terms of the agreement, Bausch Health will pay $1.75 per share in an all-cash transaction, representing an upfront consideration of approximately $63 million at closing.

The purchase price represents a premium of approximately 191% to Durect’s 30-day volume-weighted average trading price ended on July 28, 2025. The deal also includes the potential for two additional net sales milestone payments of up to $350 million in aggregate if achieved before specific deadlines.

"This announcement is fundamental progress on our Strategic Priority - Innovation," said Thomas J. Appio, Chief Executive Officer of Bausch Health. "It demonstrates our commitment to hepatology and finding new ways to address unmet medical needs."

Alcoholic hepatitis is a life-threatening form of alcohol-associated liver disease that accounted for approximately 164,000 hospital admissions in the U.S. in 2021. There is currently no FDA or EMA approved treatment for the condition.

The acquisition complements Bausch Health’s ongoing Phase 3 program for rifaximin SSD being studied in cirrhotic patients globally. A registrational Phase 3 program to evaluate larsucosterol for treating severe AH is being planned as a randomized, double-blind, placebo-controlled, multi-center study with 90-day survival as the primary endpoint.

The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions including a majority of Durect’s outstanding shares being tendered.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.